GlassScriptPhysician profile
Francesca A Wilkins
NPI 1801061486
$4,079.23
in general payments reported to CMS, 2019-2025
27 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,253 · 2020: $1,173 · 2021: $47.16 · 2022: $31.46 · 2023: $97.47 · 2024: $227 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $574.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $525.54 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $517.74 | 2019-2025 | Ozempic, Sogroya |
| Astrazeneca Pharmaceuticals LP | $457.74 | 2019-2024 | Farxiga |
| Insulet Corporation | $452.73 | 2019-2025 | Omnipod |
| Lilly USA, LLC | $326.22 | 2019-2021 | |
| Medtronic Minimed, INC. | $317.37 | 2019 | |
| Abbott Laboratories | $316.94 | 2020-2024 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Libre |
| Corcept Therapeutics | $149.91 | 2019-2025 | Korlym |
| Sunovion Pharmaceuticals INC. | $148.69 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $145.66 | 2019-2020 | |
| Amgen INC. | $140.60 | 2019-2020 | |
| Abbvie INC. | $125.71 | 2019-2020 | |
| Shire North American Group INC | $93.90 | 2019 | |
| Xeris Pharmaceuticals, INC. | $61.73 | 2020 | |
| Becton, Dickinson and Company | $41.54 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $37.93 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $35.11 | 2019 | |
| Rgh Enterprises LLC | $29.84 | 2025 | |
| Sequel Med Tech, LLC | $27.67 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $21.30 | 2019 | |
| Valeritas, INC. | $19.89 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.43 | 2020 | |
| Mannkind Corporation | $15.41 | 2019 | |
| Sanofi Pasteur INC. | $14.66 | 2023 | |
| Amarin Pharma, INC. | $14.06 | 2019 | |
| Tandem Diabetes Care, INC. | $12.91 | 2019 | |
| Senseonics, Incorporated | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francesca Wilkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.